325 related articles for article (PubMed ID: 26631616)
21. A novel non-canonical Wnt signature for prostate cancer aggressiveness.
Sandsmark E; Hansen AF; Selnæs KM; Bertilsson H; Bofin AM; Wright AJ; Viset T; Richardsen E; Drabløs F; Bathen TF; Tessem MB; Rye MB
Oncotarget; 2017 Feb; 8(6):9572-9586. PubMed ID: 28030815
[TBL] [Abstract][Full Text] [Related]
22. Hypermethylation of the GABRE~miR-452~miR-224 promoter in prostate cancer predicts biochemical recurrence after radical prostatectomy.
Kristensen H; Haldrup C; Strand S; Mundbjerg K; Mortensen MM; Thorsen K; Ostenfeld MS; Wild PJ; Arsov C; Goering W; Visakorpi T; Egevad L; Lindberg J; Grönberg H; Høyer S; Borre M; Ørntoft TF; Sørensen KD
Clin Cancer Res; 2014 Apr; 20(8):2169-81. PubMed ID: 24737792
[TBL] [Abstract][Full Text] [Related]
23. Lamin B1 promotes tumor progression and metastasis in primary prostate cancer patients.
Luo F; Han J; Chen Y; Yang K; Zhang Z; Li J
Future Oncol; 2021 Feb; 17(6):663-673. PubMed ID: 33112662
[No Abstract] [Full Text] [Related]
24. Impact of the EpCAM expression on biochemical recurrence-free survival in clinically localized prostate cancer.
Benko G; Spajić B; Krušlin B; Tomas D
Urol Oncol; 2013 May; 31(4):468-74. PubMed ID: 21514185
[TBL] [Abstract][Full Text] [Related]
25. MPC1 and MPC2 expressions are associated with favorable clinical outcomes in prostate cancer.
Li X; Ji Y; Han G; Li X; Fan Z; Li Y; Zhong Y; Cao J; Zhao J; Zhang M; Wen J; Goscinski MA; Nesland JM; Suo Z
BMC Cancer; 2016 Nov; 16(1):894. PubMed ID: 27852261
[TBL] [Abstract][Full Text] [Related]
26. Multi-institutional validation of the CAPRA-S score to predict disease recurrence and mortality after radical prostatectomy.
Punnen S; Freedland SJ; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Carroll PR; Cooperberg MR
Eur Urol; 2014 Jun; 65(6):1171-7. PubMed ID: 23587869
[TBL] [Abstract][Full Text] [Related]
27. Decreased HoxD10 Expression Promotes a Proliferative and Aggressive Phenotype in Prostate Cancer.
Mo RJ; Lu JM; Wan YP; Hua W; Liang YX; Zhuo YJ; Kuang QW; Liu YL; He HC; Zhong WD
Curr Mol Med; 2017; 17(1):70-78. PubMed ID: 28231752
[TBL] [Abstract][Full Text] [Related]
28. ARHGAP29 expression may be a novel prognostic factor of cell proliferation and invasion in prostate cancer.
Shimizu K; Matsumoto H; Hirata H; Ueno K; Samoto M; Mori J; Fujii N; Kawai Y; Inoue R; Yamamoto Y; Yano S; Shimabukuro T; Furutani-Seiki M; Matsuyama H
Oncol Rep; 2020 Dec; 44(6):2735-2745. PubMed ID: 33125156
[TBL] [Abstract][Full Text] [Related]
29. Association of plasma intermedin levels with progression and metastasis in men after radical prostatectomy for localized prostatic cancer.
Wang XL; Wang YY; He HD; Xie X; Yu ZJ; Pan YM
Cancer Biomark; 2015; 15(6):799-805. PubMed ID: 26406405
[TBL] [Abstract][Full Text] [Related]
30. Evaluating a 4-marker signature of aggressive prostate cancer using time-dependent AUC.
Gerke TA; Martin NE; Ding Z; Nuttall EJ; Stack EC; Giovannucci E; Lis RT; Stampfer MJ; Kantoff PW; Parmigiani G; Loda M; Mucci LA
Prostate; 2015 Dec; 75(16):1926-33. PubMed ID: 26469352
[TBL] [Abstract][Full Text] [Related]
31. Multi-institutional Analysis Shows that Low PCAT-14 Expression Associates with Poor Outcomes in Prostate Cancer.
White NM; Zhao SG; Zhang J; Rozycki EB; Dang HX; McFadden SD; Eteleeb AM; Alshalalfa M; Vergara IA; Erho N; Arbeit JM; Karnes RJ; Den RB; Davicioni E; Maher CA
Eur Urol; 2017 Feb; 71(2):257-266. PubMed ID: 27460352
[TBL] [Abstract][Full Text] [Related]
32. Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma.
Tsai HK; Lehrer J; Alshalalfa M; Erho N; Davicioni E; Lotan TL
BMC Cancer; 2017 Nov; 17(1):759. PubMed ID: 29132337
[TBL] [Abstract][Full Text] [Related]
33. Clinical implications of TMPRSS2-ERG gene fusion expression in patients with prostate cancer treated with radical prostatectomy.
Rubio-Briones J; Fernández-Serra A; Calatrava A; García-Casado Z; Rubio L; Bonillo MA; Iborra I; Solsona E; López-Guerrero JA
J Urol; 2010 May; 183(5):2054-61. PubMed ID: 20303538
[TBL] [Abstract][Full Text] [Related]
34. Development and validation of a novel automated Gleason grade and molecular profile that define a highly predictive prostate cancer progression algorithm-based test.
Donovan MJ; Fernandez G; Scott R; Khan FM; Zeineh J; Koll G; Gladoun N; Charytonowicz E; Tewari A; Cordon-Cardo C
Prostate Cancer Prostatic Dis; 2018 Nov; 21(4):594-603. PubMed ID: 30087426
[TBL] [Abstract][Full Text] [Related]
35. CD73 Expression Is an Independent Prognostic Factor in Prostate Cancer.
Leclerc BG; Charlebois R; Chouinard G; Allard B; Pommey S; Saad F; Stagg J
Clin Cancer Res; 2016 Jan; 22(1):158-66. PubMed ID: 26253870
[TBL] [Abstract][Full Text] [Related]
36. Genetic and cellular studies highlight that A Disintegrin and Metalloproteinase 19 is a protective biomarker in human prostate cancer.
Hoyne G; Rudnicka C; Sang QX; Roycik M; Howarth S; Leedman P; Schlaich M; Candy P; Matthews V
BMC Cancer; 2016 Feb; 16():151. PubMed ID: 26912236
[TBL] [Abstract][Full Text] [Related]
37. Enhanced expression of centromere protein F predicts clinical progression and prognosis in patients with prostate cancer.
Zhuo YJ; Xi M; Wan YP; Hua W; Liu YL; Wan S; Zhou YL; Luo HW; Wu SL; Zhong WD; Wu CL
Int J Mol Med; 2015 Apr; 35(4):966-72. PubMed ID: 25647485
[TBL] [Abstract][Full Text] [Related]
38. KDM5C is overexpressed in prostate cancer and is a prognostic marker for prostate-specific antigen-relapse following radical prostatectomy.
Stein J; Majores M; Rohde M; Lim S; Schneider S; Krappe E; Ellinger J; Dietel M; Stephan C; Jung K; Perner S; Kristiansen G; Kirfel J
Am J Pathol; 2014 Sep; 184(9):2430-7. PubMed ID: 25016185
[TBL] [Abstract][Full Text] [Related]
39. Identification of a candidate prognostic gene signature by transcriptome analysis of matched pre- and post-treatment prostatic biopsies from patients with advanced prostate cancer.
Rajan P; Stockley J; Sudbery IM; Fleming JT; Hedley A; Kalna G; Sims D; Ponting CP; Heger A; Robson CN; McMenemin RM; Pedley ID; Leung HY
BMC Cancer; 2014 Dec; 14():977. PubMed ID: 25519703
[TBL] [Abstract][Full Text] [Related]
40. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy.
Rosenbaum E; Hoque MO; Cohen Y; Zahurak M; Eisenberger MA; Epstein JI; Partin AW; Sidransky D
Clin Cancer Res; 2005 Dec; 11(23):8321-5. PubMed ID: 16322291
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
